BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21870054)

  • 1. Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia.
    Lacoma A; Rodríguez N; Prat C; Ruiz-Manzano J; Andreo F; Ramírez A; Bas A; Pérez M; Ausina V; Domínguez J
    Eur J Clin Microbiol Infect Dis; 2012 May; 31(5):825-33. PubMed ID: 21870054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial procalcitonin levels for predicting prognosis in community-acquired pneumonia.
    Ito A; Ishida T; Tachibana H; Ito Y; Takaiwa T
    Respirology; 2016 Nov; 21(8):1459-1464. PubMed ID: 27398948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of inflammatory and cardiovascular biomarkers with pneumonia severity scores.
    Lacoma A; Bas A; Tudela P; Giménez M; Mòdol JM; Pérez M; Ausina V; Dominguez J; Prat-Aymerich C
    Enferm Infecc Microbiol Clin; 2014 Mar; 32(3):140-6. PubMed ID: 24054971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia.
    Prat C; Lacoma A; Dominguez J; Papassotiriou J; Morgenthaler NG; Andreo F; Tudela P; Ruiz-Manzano J; Ausina V
    J Infect; 2007 Nov; 55(5):400-7. PubMed ID: 17825918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Study of Presepsin as an Indicator of the Severity of Community-Acquired Pneumonia in Emergency Departments: Comparison with Pneumonia Severity Index and CURB-65 Scores.
    Ham JY; Song KE
    Lab Med; 2019 Oct; 50(4):364-369. PubMed ID: 30892617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ.
    Krüger S; Papassotiriou J; Marre R; Richter K; Schumann C; von Baum H; Morgenthaler NG; Suttorp N; Welte T;
    Intensive Care Med; 2007 Dec; 33(12):2069-78. PubMed ID: 17938883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study.
    Ito A; Ito I; Inoue D; Marumo S; Ueda T; Nakagawa H; Taki M; Nakagawa A; Tatsumi S; Nishimura T; Shiota T; Ishida T
    Int J Infect Dis; 2020 Mar; 92():228-233. PubMed ID: 31981766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ.
    Krüger S; Ewig S; Kunde J; Hartmann O; Suttorp N; Welte T;
    Thorax; 2010 Mar; 65(3):208-14. PubMed ID: 20335288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia.
    Masiá M; Papassotiriou J; Morgenthaler NG; Hernández I; Shum C; Gutiérrez F
    Clin Chem; 2007 Dec; 53(12):2193-201. PubMed ID: 17951293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of serum procalcitonin, C-reactive protein, soluble triggering receptor expressed on myeloid cells 1 and Clinical Pulmonary Infection Score for evaluation of severity and prognosis of community-acquired pneumonia in elderly patients.
    Wang Y; Zhang S; Li L; Xie J
    Arch Gerontol Geriatr; 2019; 80():53-57. PubMed ID: 30366226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ.
    Krüger S; Ewig S; Papassotiriou J; Kunde J; Marre R; von Baum H; Suttor N; Welte T;
    Respir Res; 2009 Jul; 10(1):65. PubMed ID: 19594893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.
    Müller B; Süess E; Schuetz P; Müller C; Bingisser R; Bergmann A; Stolz D; Tamm M; Morgenthaler NG; Christ-Crain M
    J Intern Med; 2006 Dec; 260(6):568-76. PubMed ID: 17116008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP).
    Tamura M; Watanabe M; Nakajima A; Kurai D; Ishii H; Takata S; Nakamoto K; Sohara E; Honda K; Nakamura M; Inui T; Wada H; Takizawa H; Goto H
    J Infect Chemother; 2014 Feb; 20(2):97-103. PubMed ID: 24462441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
    Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
    Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia.
    España PP; Capelastegui A; Bilbao A; Diez R; Izquierdo F; Lopez de Goicoetxea MJ; Gamazo J; Medel F; Salgado J; Gorostiaga I; Quintana JM;
    Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3397-405. PubMed ID: 23010902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procalcitonin is not an independent predictor of 30-day mortality, albeit predicts pneumonia severity in patients with pneumonia acquired outside the hospital.
    Akagi T; Nagata N; Miyazaki H; Harada T; Takeda S; Yoshida Y; Wada K; Fujita M; Watanabe K
    BMC Geriatr; 2019 Jan; 19(1):3. PubMed ID: 30616612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procalcitonin kinetics in Legionella pneumophila pneumonia.
    de Jager CP; de Wit NC; Weers-Pothoff G; van der Poll T; Wever PC
    Clin Microbiol Infect; 2009 Nov; 15(11):1020-5. PubMed ID: 19438643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.
    Heining L; Giesa C; Ewig S
    Lung; 2016 Apr; 194(2):185-91. PubMed ID: 26748496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of procalcitonin for differentiating cryptogenic organising pneumonia from community-acquired pneumonia.
    Ito A; Ishida T; Tachibana H; Arita M; Yamazaki A; Washio Y
    Clin Chem Lab Med; 2019 Sep; 57(10):1632-1637. PubMed ID: 31120857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.